image description

Press Releases

Press Releases

October 14, 2019
Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne
- Mark Foley to lead company as it gears up to commercialize next-generation neuromodulator – - Change in leadership unrelated to company performance - - Revance on track to submit BLA for DAXI for the treatment of glabellar lines in the Fall of 2019, as previously announced - NEWARK, Calif.
October 2, 2019
Revance Earns Great Place to Work® Certification for Second Year
  NEWARK, Calif. --(BUSINESS WIRE)--Oct. 2, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by the independent analysts at
September 25, 2019
Revance to Participate in the 2019 Cantor Global Healthcare Conference
  NEWARK, Calif. --(BUSINESS WIRE)--Sep. 25, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019 Cantor Global Healthcare
August 28, 2019
Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Aug. 28, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells Fargo 14th Annual Healthcare
July 17, 2019
Revance Adds Life Sciences Audit Executive Chris Nolet to Board of Directors
- Nolet will serve as Chair of the Audit Committee - NEWARK, Calif. --(BUSINESS WIRE)--Jul. 17, 2019-- ​ Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today
June 6, 2019
Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors
- Beraud will also chair newly-formed Brand Strategy Committee - NEWARK, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic
Displaying 1 - 10 of 176